Possible Orange Book Revisions Back In Play With US FDA Report To Congress

 
• By Brenda Sandburg

Agency is setting up an internal working group to assess whether certain patent information should be included or removed from the Orange Book. PhRMA, AAM and others address therapeutic equivalence ratings and listing of device-related and REMS-related patents.

US FDA is evaluating whether to make improvements to its Orange Book • Source: Alamy

More from US FDA

More from Agency Leadership